<p>在過去的 7 天裏，美國市場下跌了 2.5%，但在過去一年中上漲了 23%，預計未來幾年收益將以每年 17% 的速度增長。在這種環境下，識別可能低於其估計價值的股票可以為尋求利用未來增長前景的投資者提供潛在機會。</p>
<h3>基於現金流的美國十大被低估股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估計）</strong></td>
<td><strong>折扣（估計）</strong></td>
</tr>
<tr>
<td>Solstice Advanced Materials (SOLS)</td>
<td>$81.02</td>
<td>$156.32</td>
<td>48.2%</td>
</tr>
<tr>
<td>Robert Half (RHI)</td>
<td>$31.26</td>
<td>$60.09</td>
<td>48%</td>
</tr>
<tr>
<td>Rayonier (RYN)</td>
<td>$20.97</td>
<td>$40.79</td>
<td>48.6%</td>
</tr>
<tr>
<td>MercadoLibre (MELI)</td>
<td>$1607.80</td>
<td>$3085.44</td>
<td>47.9%</td>
</tr>
<tr>
<td>Live Oak Bancshares (LOB)</td>
<td>$37.41</td>
<td>$74.21</td>
<td>49.6%</td>
</tr>
<tr>
<td>Lazard (LAZ)</td>
<td>$46.36</td>
<td>$91.21</td>
<td>49.2%</td>
</tr>
<tr>
<td>Inter &amp; Co (INTR)</td>
<td>$5.67</td>
<td>$10.91</td>
<td>48%</td>
</tr>
<tr>
<td>Cactus (WHD)</td>
<td>$56.62</td>
<td>$111.45</td>
<td>49.2%</td>
</tr>
<tr>
<td>BlackSky Technology (BKSY)</td>
<td>$34.76</td>
<td>$68.23</td>
<td>49.1%</td>
</tr>
<tr>
<td>AbbVie (ABBV)</td>
<td>$227.23</td>
<td>$444.25</td>
<td>48.9%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們基於現金流的 140 只被低估美國股票的完整列表。</p>
<p>讓我們更仔細地看看我們篩選出的幾隻股票。</p>
<h2>Travere Therapeutics (TVTX)</h2>
<p><strong>概述：</strong> Travere Therapeutics, Inc.是一家生物製藥公司，專注於識別、開發和提供針對美國罕見腎臟和代謝疾病的療法，市值為 42.6 億美元。</p>
<p><strong>運營：</strong> 公司的收入主要來自創新療法的開發和商業化，金額為 5.362 億美元。</p>
<p><strong>公允價值折扣估計：</strong> 46.6%</p>
<p>根據現金流分析，Travere Therapeutics 似乎被低估，當前交易價格為 45.81 美元，而未來現金流價值估計為 85.85 美元。儘管近期內部人士出售股票和股價波動，該公司顯示出強勁的收入增長潛力，年增長率為 22.4%，超過市場的 11.8%。最近 FDA 批准 FILSPARI 用於治療 FSGS，顯著擴大了其可服務市場，可能增強未來三年的現金流和盈利能力預期。</p>
<ul>
<li>我們在 Travere Therapeutics 增長報告中詳細分析的內容暗示了未來強勁的財務表現。</li>
<li>在這份財務健康報告中解鎖我們對 Travere Therapeutics 股票分析的全面見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8a367f73-a6f2-4b6f-b781-0538bd368fa3/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8a367f73-a6f2-4b6f-b781-0538bd368fa3/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>截至 2026 年 6 月的 TVTX 折現現金流</p>
<h2>Goosehead Insurance (GSHD)</h2>
<p><strong>概述：</strong> Goosehead Insurance, Inc.作為 Goosehead Financial, LLC 的控股公司，在美國提供個人保險代理服務，市值約為 13.7 億美元。</p>
<p><strong>運營：</strong> 公司的收入主要來自其保險分銷部門，產生了 3.822 億美元的收入。</p>
<p><strong>公允價值折扣估計：</strong> 42%</p>
<p>Goosehead Insurance 的交易價格為 38.35 美元，低於其未來現金流價值估計的 66.13 美元，表明被低估。該公司報告 2026 年第一季度收入為 9308 萬美元，淨收入為 489 萬美元，反映出強勁的財務表現，盈利增長年率為 21.7%，超過市場的 16.8%。儘管債務水平較高且股東權益為負，但總計 1.3151 億美元的股票回購可能會增強未來的股東價值。</p>
<ul>
<li>我們的綜合增長報告提出了 Goosehead Insurance 有望實現顯著財務增長的可能性。</li>
<li>在這裏深入瞭解 Goosehead Insurance 的完整分析健康報告。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a5f09225-d683-4366-a9bc-a20145f11454/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a5f09225-d683-4366-a9bc-a20145f11454/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>截至 2026 年 6 月的 GSHD 折現現金流</p>
<h2>National Bank Holdings (NBHC)</h2>
<p><strong>概述：</strong> National Bank Holdings Corporation，市值為 18.9 億美元，作為 NBH Bank 的銀行控股公司，向美國的商業、企業和消費者客户提供一系列銀行產品和金融服務。</p>
<p><strong>運營：</strong> 公司的收入主要來自其銀行部門，產生了 4.2918 億美元的收入。</p>
<p><strong>公允價值折扣估計：</strong> 21.2%</p>
<p>National Bank Holdings 的交易價格為 42.19 美元，低於其估計的未來現金流價值 53.51 美元，表明其被低估超過 20%。預計該公司的收益將顯著增長，年增長率為 30.7%，超過美國市場平均水平。最近的財務數據顯示，2026 年第一季度淨利息收入增加至 1.088 億美元，儘管淨收入較去年下降至 2079 萬美元。最近回購價值 1611 萬美元的股票可能會支持股東價值，儘管過去存在稀釋擔憂。</p>
<ul>
<li>我們的收益增長報告揭示了 National Bank Holdings 未來業績顯著增長的潛力。</li>
<li>在這裏通過我們的綜合財務健康報告深入瞭解 National Bank Holdings 的複雜情況。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8e2e7225-a0e6-47c3-8635-c7104af5c872/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8e2e7225-a0e6-47c3-8635-c7104af5c872/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>截至 2026 年 6 月的 NBHC 折現現金流</p>
<h2>總結</h2>
<ul>
<li>通過使用我們的篩選器，深入瞭解所有 140 只基於現金流的被低估美國股票。</li>
<li>擁有這些公司的股份？將您的持股整合到 Simply Wall St 的投資組合中，以獲取通知和詳細的股票報告。</li>
<li>使用 Simply Wall St 的應用程序簡化您的投資策略，免費獲取全球各地股票的廣泛研究。</li>
</ul>
<h2>準備好嘗試不同的方法了嗎？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過提供可靠收入來源的穩健分紅支付者來多樣化您的投資組合，以應對潛在的市場動盪。</li>
<li>通過分析師和管理層的樂觀展望，推動您的投資組合中顯示出強勁增長潛力的公司。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章是一般性的。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不旨在提供財務建議。它不構成買入或賣出任何股票的推薦，也不考慮您的目標或財務狀況。</strong> 我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>
<h3><strong>新功能：</strong> 在一個地方管理您所有的股票投資組合</h3>
<p>我們為股票投資者創建了 <strong>終極投資組合助手</strong>，<strong>而且是免費的。</strong></p>
<p>• 連接無限數量的投資組合，並以一種貨幣查看您的總額</p>
<p>• 通過電子郵件或手機接收新的警告信號或風險提示</p>
<p>• 跟蹤您股票的公允價值</p>
<p>免費試用演示投資組合</p>

SOLS

NBHC

TVTX

拉美商業服務

鵝頭保險

KMLI

<p>Simply Wall St 根據現金流分析識別出到 2026 年 6 月可能被低估的美國股票。推薦的股票包括 Travere Therapeutics (TVTX)、Goosehead Insurance (GSHD) 和 National Bank Holdings (NBHC)，這些股票的交易價格均低於估計的公允價值，並且預計有強勁的盈利增長。文章還列出了其他一些被低估的優質股票，如 Solstice Advanced Materials 和 MercadoLibre，建議在市場波動中尋找投資機會</p>

<p>Over the last 7 days, the United States market has dropped 2.5%, yet it has risen by 23% over the past year, with earnings expected to grow by 17% annually in the coming years. In this environment, identifying stocks that may be priced below their estimated value can offer potential opportunities for investors seeking to capitalize on future growth prospects.</p>
<div class="lb-trans"><p>在過去的 7 天裏，美國市場下跌了 2.5%，但在過去一年中上漲了 23%，預計未來幾年收益將以每年 17% 的速度增長。在這種環境下，識別可能低於其估計價值的股票可以為尋求利用未來增長前景的投資者提供潛在機會。</p>
</div><h3>Top 10 Undervalued Stocks Based On Cash Flows In The United States</h3>
<div class="lb-trans"><h3>基於現金流的美國十大被低估股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Current Price</strong></td>
<td><strong>Fair Value (Est)</strong></td>
<td><strong>Discount (Est)</strong></td>
</tr>
<tr>
<td>Solstice Advanced Materials (SOLS)</td>
<td>$81.02</td>
<td>$156.32</td>
<td>48.2%</td>
</tr>
<tr>
<td>Robert Half (RHI)</td>
<td>$31.26</td>
<td>$60.09</td>
<td>48%</td>
</tr>
<tr>
<td>Rayonier (RYN)</td>
<td>$20.97</td>
<td>$40.79</td>
<td>48.6%</td>
</tr>
<tr>
<td>MercadoLibre (MELI)</td>
<td>$1607.80</td>
<td>$3085.44</td>
<td>47.9%</td>
</tr>
<tr>
<td>Live Oak Bancshares (LOB)</td>
<td>$37.41</td>
<td>$74.21</td>
<td>49.6%</td>
</tr>
<tr>
<td>Lazard (LAZ)</td>
<td>$46.36</td>
<td>$91.21</td>
<td>49.2%</td>
</tr>
<tr>
<td>Inter &amp; Co (INTR)</td>
<td>$5.67</td>
<td>$10.91</td>
<td>48%</td>
</tr>
<tr>
<td>Cactus (WHD)</td>
<td>$56.62</td>
<td>$111.45</td>
<td>49.2%</td>
</tr>
<tr>
<td>BlackSky Technology (BKSY)</td>
<td>$34.76</td>
<td>$68.23</td>
<td>49.1%</td>
</tr>
<tr>
<td>AbbVie (ABBV)</td>
<td>$227.23</td>
<td>$444.25</td>
<td>48.9%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估計）</strong></td>
<td><strong>折扣（估計）</strong></td>
</tr>
<tr>
<td>Solstice Advanced Materials (SOLS)</td>
<td>$81.02</td>
<td>$156.32</td>
<td>48.2%</td>
</tr>
<tr>
<td>Robert Half (RHI)</td>
<td>$31.26</td>
<td>$60.09</td>
<td>48%</td>
</tr>
<tr>
<td>Rayonier (RYN)</td>
<td>$20.97</td>
<td>$40.79</td>
<td>48.6%</td>
</tr>
<tr>
<td>MercadoLibre (MELI)</td>
<td>$1607.80</td>
<td>$3085.44</td>
<td>47.9%</td>
</tr>
<tr>
<td>Live Oak Bancshares (LOB)</td>
<td>$37.41</td>
<td>$74.21</td>
<td>49.6%</td>
</tr>
<tr>
<td>Lazard (LAZ)</td>
<td>$46.36</td>
<td>$91.21</td>
<td>49.2%</td>
</tr>
<tr>
<td>Inter &amp; Co (INTR)</td>
<td>$5.67</td>
<td>$10.91</td>
<td>48%</td>
</tr>
<tr>
<td>Cactus (WHD)</td>
<td>$56.62</td>
<td>$111.45</td>
<td>49.2%</td>
</tr>
<tr>
<td>BlackSky Technology (BKSY)</td>
<td>$34.76</td>
<td>$68.23</td>
<td>49.1%</td>
</tr>
<tr>
<td>AbbVie (ABBV)</td>
<td>$227.23</td>
<td>$444.25</td>
<td>48.9%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 140 stocks from our Undervalued US Stocks Based On Cash Flows screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們基於現金流的 140 只被低估美國股票的完整列表。</p>
</div><p>Let's take a closer look at a couple of our picks from the screened companies.</p>
<div class="lb-trans"><p>讓我們更仔細地看看我們篩選出的幾隻股票。</p>
</div><h2>Travere Therapeutics (TVTX)</h2>
<div class="lb-trans"><h2>Travere Therapeutics (TVTX)</h2>
</div><p><strong>Overview:</strong> Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering therapies for rare kidney and metabolic diseases in the United States, with a market cap of $4.26 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Travere Therapeutics, Inc.是一家生物製藥公司，專注於識別、開發和提供針對美國罕見腎臟和代謝疾病的療法，市值為 42.6 億美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from the development and commercialization of innovative therapies, amounting to $536.20 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自創新療法的開發和商業化，金額為 5.362 億美元。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 46.6%</p>
<div class="lb-trans"><p><strong>公允價值折扣估計：</strong> 46.6%</p>
</div><p>Travere Therapeutics appears undervalued based on cash flow analysis, trading at US$45.81 compared to a future cash flow value estimate of US$85.85. Despite recent insider selling and share price volatility, the company shows strong revenue growth potential at 22.4% annually, outpacing the market's 11.8%. Recent FDA approval for FILSPARI in treating FSGS expands its addressable market significantly, potentially enhancing future cash flows and profitability projections over the next three years.</p>
<div class="lb-trans"><p>根據現金流分析，Travere Therapeutics 似乎被低估，當前交易價格為 45.81 美元，而未來現金流價值估計為 85.85 美元。儘管近期內部人士出售股票和股價波動，該公司顯示出強勁的收入增長潛力，年增長率為 22.4%，超過市場的 11.8%。最近 FDA 批准 FILSPARI 用於治療 FSGS，顯著擴大了其可服務市場，可能增強未來三年的現金流和盈利能力預期。</p>
</div><ul>
<li>The analysis detailed in our Travere Therapeutics growth report hints at robust future financial performance.</li>
<li>Unlock comprehensive insights into our analysis of Travere Therapeutics stock in this financial health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們在 Travere Therapeutics 增長報告中詳細分析的內容暗示了未來強勁的財務表現。</li>
<li>在這份財務健康報告中解鎖我們對 Travere Therapeutics 股票分析的全面見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8a367f73-a6f2-4b6f-b781-0538bd368fa3/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/8a367f73-a6f2-4b6f-b781-0538bd368fa3/chart/dcf?theme=light"/></p>
<p>TVTX Discounted Cash Flow as at Jun 2026</p>
<div class="lb-trans"><p>截至 2026 年 6 月的 TVTX 折現現金流</p>
</div><h2>Goosehead Insurance (GSHD)</h2>
<div class="lb-trans"><h2>Goosehead Insurance (GSHD)</h2>
</div><p><strong>Overview:</strong> Goosehead Insurance, Inc. operates as a holding company for Goosehead Financial, LLC, offering personal lines insurance agency services in the United States with a market cap of approximately $1.37 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Goosehead Insurance, Inc.作為 Goosehead Financial, LLC 的控股公司，在美國提供個人保險代理服務，市值約為 13.7 億美元。</p>
</div><p><strong>Operations:</strong> The company's revenue primarily comes from its insurance distribution segment, which generated $382.20 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自其保險分銷部門，產生了 3.822 億美元的收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 42%</p>
<div class="lb-trans"><p><strong>公允價值折扣估計：</strong> 42%</p>
</div><p>Goosehead Insurance is trading at US$38.35, below its future cash flow value estimate of US$66.13, suggesting undervaluation. The company reported Q1 2026 revenue of US$93.08 million and net income of US$4.89 million, reflecting strong financial performance with earnings growth outpacing the market at 21.7% annually versus 16.8%. Despite high debt levels and negative equity, significant share buybacks totaling US$131.51 million may enhance shareholder value moving forward.</p>
<div class="lb-trans"><p>Goosehead Insurance 的交易價格為 38.35 美元，低於其未來現金流價值估計的 66.13 美元，表明被低估。該公司報告 2026 年第一季度收入為 9308 萬美元，淨收入為 489 萬美元，反映出強勁的財務表現，盈利增長年率為 21.7%，超過市場的 16.8%。儘管債務水平較高且股東權益為負，但總計 1.3151 億美元的股票回購可能會增強未來的股東價值。</p>
</div><ul>
<li>Our comprehensive growth report raises the possibility that Goosehead Insurance is poised for substantial financial growth.</li>
<li>Delve into the full analysis health report here for a deeper understanding of Goosehead Insurance.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們的綜合增長報告提出了 Goosehead Insurance 有望實現顯著財務增長的可能性。</li>
<li>在這裏深入瞭解 Goosehead Insurance 的完整分析健康報告。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a5f09225-d683-4366-a9bc-a20145f11454/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/a5f09225-d683-4366-a9bc-a20145f11454/chart/dcf?theme=light"/></p>
<p>GSHD Discounted Cash Flow as at Jun 2026</p>
<div class="lb-trans"><p>截至 2026 年 6 月的 GSHD 折現現金流</p>
</div><h2>National Bank Holdings (NBHC)</h2>
<div class="lb-trans"><h2>National Bank Holdings (NBHC)</h2>
</div><p><strong>Overview:</strong> National Bank Holdings Corporation, with a market cap of $1.89 billion, operates as the bank holding company for NBH Bank, offering a range of banking products and financial services to commercial, business, and consumer clients in the United States.</p>
<div class="lb-trans"><p><strong>概述：</strong> National Bank Holdings Corporation，市值為 18.9 億美元，作為 NBH Bank 的銀行控股公司，向美國的商業、企業和消費者客户提供一系列銀行產品和金融服務。</p>
</div><p><strong>Operations:</strong> The company's revenue primarily comes from its banking segment, which generated $429.18 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自其銀行部門，產生了 4.2918 億美元的收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 21.2%</p>
<div class="lb-trans"><p><strong>公允價值折扣估計：</strong> 21.2%</p>
</div><p>National Bank Holdings is trading at US$42.19, below its estimated future cash flow value of US$53.51, indicating it is undervalued by over 20%. The company's earnings are forecast to grow significantly at 30.7% annually, surpassing the US market average. Recent financials show net interest income increased to US$108.8 million in Q1 2026, though net income decreased to US$20.79 million from a year ago. A recent buyback of shares worth $16.11 million may support shareholder value despite past dilution concerns.</p>
<div class="lb-trans"><p>National Bank Holdings 的交易價格為 42.19 美元，低於其估計的未來現金流價值 53.51 美元，表明其被低估超過 20%。預計該公司的收益將顯著增長，年增長率為 30.7%，超過美國市場平均水平。最近的財務數據顯示，2026 年第一季度淨利息收入增加至 1.088 億美元，儘管淨收入較去年下降至 2079 萬美元。最近回購價值 1611 萬美元的股票可能會支持股東價值，儘管過去存在稀釋擔憂。</p>
</div><ul>
<li>Our earnings growth report unveils the potential for significant increases in National Bank Holdings' future results.</li>
<li>Navigate through the intricacies of National Bank Holdings with our comprehensive financial health report here.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們的收益增長報告揭示了 National Bank Holdings 未來業績顯著增長的潛力。</li>
<li>在這裏通過我們的綜合財務健康報告深入瞭解 National Bank Holdings 的複雜情況。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8e2e7225-a0e6-47c3-8635-c7104af5c872/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/8e2e7225-a0e6-47c3-8635-c7104af5c872/chart/dcf?theme=light"/></p>
<p>NBHC Discounted Cash Flow as at Jun 2026</p>
<div class="lb-trans"><p>截至 2026 年 6 月的 NBHC 折現現金流</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>總結</h2>
</div><ul>
<li>Get an in-depth perspective on all 140 Undervalued US Stocks Based On Cash Flows by using our screener here.</li>
<li>Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.</li>
<li>Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過使用我們的篩選器，深入瞭解所有 140 只基於現金流的被低估美國股票。</li>
<li>擁有這些公司的股份？將您的持股整合到 Simply Wall St 的投資組合中，以獲取通知和詳細的股票報告。</li>
<li>使用 Simply Wall St 的應用程序簡化您的投資策略，免費獲取全球各地股票的廣泛研究。</li>
</ul>
</div><h2>Ready For A Different Approach?</h2>
<div class="lb-trans"><h2>準備好嘗試不同的方法了嗎？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過提供可靠收入來源的穩健分紅支付者來多樣化您的投資組合，以應對潛在的市場動盪。</li>
<li>通過分析師和管理層的樂觀展望，推動您的投資組合中顯示出強勁增長潛力的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章是一般性的。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不旨在提供財務建議。它不構成買入或賣出任何股票的推薦，也不考慮您的目標或財務狀況。</strong> 我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> 在一個地方管理您所有的股票投資組合</h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我們為股票投資者創建了 <strong>終極投資組合助手</strong>，<strong>而且是免費的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 連接無限數量的投資組合，並以一種貨幣查看您的總額</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通過電子郵件或手機接收新的警告信號或風險提示</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟蹤您股票的公允價值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免費試用演示投資組合</p>
</div>

三隻股票可能在 2026 年 6 月的價格低於其預估價值